these are some good numbers
the myocardia deal earlier this week is just another example of how Bio Pharma Deal with some patience and good leadership & product can really don well
it takes time to get Their house in order (Bene deal, SAS results, NFL exposure etc) but when P3 begins and goes well (fingers crossed) then the results should be just a confirmatory study of what we already know which is circa 45-55 in WOMAC pain reduction.
Throw in a Pharma Licence deal or a rebuffed take over deal and then anything is possible.
I remember @moz posting something a while back about how the Top 20 shareholders don’t need really change from year to year which is a great thing. This will be our biggest weapon on rebuffing a buy out in favour of a license agreement
Chart, page-1322
-
- There are more pages in this discussion • 2,973 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78837 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36290 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |